Immunotherapy of Congenital SIV Infection.
Abstract
During the no-cost extension, the animals enrolled in the DNA vaccine study received 2 protein boosts with recombinant gpl 60 derived from HIVIlIB. We have enrolled another control group of 4 age-matched rhesus macaques that received only the 2 gpl 60 boosts. At the time of challenge, several animals had developed high levels of neutralizing antibodies. A few weeks ago, all animals were challenged with 1 0 animal infectious doses of the homologous SHlV-vpu+, a chimeric strain that contains the HIVIlIB env gene. While early results indicate that some animals may have been protected against virus challenge, longer follow up will be required to determine the outcome.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1998
- Accession Number
- ADA358457
Entities
People
- Ruth M. Rupprecht
Organizations
- Dana–Farber Cancer Institute